MARKET

TPST

TPST

Tempest Therapeutics Inc
NASDAQ
2.850
-0.060
-2.06%
After Hours: 3.980 +1.13 +39.65% 19:59 06/18 EDT
OPEN
2.920
PREV CLOSE
2.910
HIGH
3.000
LOW
2.830
VOLUME
939.31K
TURNOVER
0
52 WEEK HIGH
9.77
52 WEEK LOW
0.1700
MARKET CAP
63.32M
P/E (TTM)
-1.6213
1D
5D
1M
3M
1Y
5Y
Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
Tempest Therapeutics, Inc. Plans to report new data from the global randomized Phase 1b/2 combination study of hepatocellular carcinoma on June 20, 2024. The company is developing first-in-classi targeted and immune-mediated therapeutics to fight cancer.
Barchart · 23h ago
Weekly Report: what happened at TPST last week (0610-0614)?
Weekly Report · 2d ago
Tempest Therapeutics Inc: Statement of changes in beneficial ownership of securities
Press release · 4d ago
Weekly Report: what happened at TPST last week (0603-0607)?
Weekly Report · 06/10 11:32
Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Tempest Therapeutics, Inc. Is a clinical-stage biotechnology company developing first-in-class targeted and immune-mediated therapeutics to fight cancer. The company granted one employee nonqualified stock options to purchase 14,000 shares of its common stock in 2024.
Barchart · 06/07 03:30
Weekly Report: what happened at TPST last week (0527-0531)?
Weekly Report · 06/03 11:35
Glancy Prongay & Murray LLP Announces Investigation of Tempest Therapeutics, Inc. (TPST)
Glancy Prongay & Murray LLP announces its investigation of Tempest Therapeutics, Inc. Concerning the Company and its directors’ and officers’ possible violations of state laws. This press release may be considered Attorney Advertising in some jurisdictions. GPM is investigating the Company.
Barchart · 05/31 14:45
Weekly Report: what happened at TPST last week (0520-0524)?
Weekly Report · 05/27 11:40
More
About TPST
Tempest Therapeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495. TPST-1120 is a selective antagonist of peroxisome proliferator-activated receptor alpha (PPAR). The ongoing global randomized Phase Ib/II trial of TPST-1120 combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma (HCC). The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, is in an ongoing Phase I combination trial in patients with endometrial cancer.

Webull offers Tempest Therapeutics Inc stock information, including NASDAQ: TPST real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TPST stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading TPST stock methods without spending real money on the virtual paper trading platform.